Alnylam Pharmaceuticals stock target cut to 250 dollars by H.C. Wainwright
Published on 11/17/2026 at 22:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst action resets valuation debate
- H.C. Wainwright retained its Buy rating while lowering its price target.
- The firm cited slower Amvuttra starts and tighter first-line access.
- Alnylam is scheduled to present at the Jefferies Global Healthcare Conference on November 18.
H.C. Wainwright cut its price target for Alnylam Pharmaceuticals from 455 to 250 US dollars on Tuesday, November 17, while retaining a Buy rating. Markets Insider reported that the analyst cited slower Amvuttra starts and tighter first-line access.
Access concerns weigh on outlook
The move leaves the Buy recommendation unchanged but signals a more cautious valuation view for the RNA interference specialist. Amvuttra is Alnylam's main commercial growth driver in transthyretin amyloidosis, making patient starts and reimbursement access important indicators for future sales.
Alnylam reported third-quarter results on October 29. The company has also highlighted five-year HELIOS-B data for Amvuttra in ATTR-CM and announced a 1 billion US dollar share repurchase program earlier in November.
Next scheduled investor appearance
Alnylam lists the Jefferies Global Healthcare Conference for November 18 at 10:00 a.m. Eastern Time. The event is the next scheduled investor presentation shown on the company's investor relations site.
Alnylam Pharmaceuticals stock traded at 141.70 euros on Lang & Schwarz at 22:20 CET on Tuesday, November 17.
Alnylam Pharmaceuticals at a glance
- Company: Alnylam Pharmaceuticals
- ISIN: US02043Q1076
- Ticker: ALNY
- Lang & Schwarz quote: 141.70 euros on November 17, 2026 at 22:20 CET
The broader US market environment is covered through the S&P 500.
